RxDoctor Payments Data

Sailesh Shah, MD

Interventional Cardiology · Sacramento, CANPI 1881681930

Payments from drug & device makers

$11,419in general payments, 2019–2025

Across 76 payments — averaging $150.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Artivion, Inc.$7K
  • Biotronik Inc.$771
  • Abiomed$651
  • Novo Nordisk$618
  • W. L. Gore & Associates, Inc.$592
  • Amgen$207
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$5,00044%
  • Travel & lodging$2,74524%
  • Food & beverage$3,67032%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,419 in reported general payments places this provider in the 50th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$231,346
Medicare patients
657
Services billed
1,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban252$303,683
XareltoRivaroxaban129$157,436
EntrestoSacubitril/Valsartan53$71,878
BrilintaTicagrelor86$64,192
Repatha SureclickEvolocumab64$54,806
OzempicSemaglutide34$33,592
FarxigaDapagliflozin Propanediol19$29,269
MultaqDronedarone Hcl21$22,876
JardianceEmpagliflozin13$18,228
Repatha PushtronexEvolocumab14$11,411
Icosapent Ethyl22$5,261
Metoprolol Succinate331$4,307
Olmesartan Medoxomil193$4,161
Ranolazine ErRanolazine42$3,947
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid12$3,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$21$157,436129 claims
AstraZenecaBrilinta, Farxiga$18$93,461105 claims
Novo NordiskOzempic$618$33,59234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →